SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer ...

The company's last quarterly earnings report, which we covered last week, showed Resmed bringing home US$1.22 billion in revenues for the three months to 30 September. That was an 11% rise ...

Here's why Selector sees ResMed shares as a standout for the year ahead. Selector's High Conviction Equity Fund put up 11% returns for the three months ended September 30, helped in part by ResMed ...

Analysts reckon Ozempic-style obesity drugs won’t affect Resmed’s fortunes – at least in the short ... having surged 8% since Friday numbers showing an 11% revenue surge to US$1.224 billion and 35% ...

Revenue: US$1.22b (up 11% from 1Q 2024). Net income: US$311.4m (up 42% from 1Q 2024). Profit margin: 25% (up from 20% in 1Q 2024). The increase in margin was driven by higher revenue. EPS ...

as we get full AirSense 11 capabilities, everyone who's at that five-year point gets the chance to say, ‘Yes, I want the latest and greatest therapy.’” ‘It will be a benign pricing environment’ ...

We will see ongoing momentum. Our masks and accessories business had another strong quarter, delivering 11% year-over-year growth. The AirFit F40, ResMed's smallest oronasal mask ever, continues ...

Masks and Accessories Sales Growth: Increased by 11% globally. Residential Care Software Revenue: Increased by 12%. ResMed Inc (NYSE:RMD) reported a strong quarter with an 11% revenue growth ...

ResMed stands to benefit from Philips’ significant product recall and the launch of its new flagship product, AirSense 11. Market share gains from Philips’ product recall may be limited as ...

ResMed's significant 11% year-over-year revenue growth was primarily propelled by innovations and strong demand for its sleep devices and masks. The gross margin boost was aided by manufacturing ...